Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.69 |
| ▸ | HPGD | P15428 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.52 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.51 |
| ▸ | POLR1A | O95602 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12447795 | 0.83 | HPGD (0.71) | ALDH1A1KDM4EHPGDSMN1; SMN2LMNA | |
| Salethamide SCHEMBL588724 | 0.83 | ALDH1A1 (0.71) | ALDH1A1KDM4EHPGDSMN1; SMN2LMNA | |
| SCHEMBL24503506 | 0.83 | ALDH1A1 (0.71) | ALDH1A1KDM4EHPGDSMN1; SMN2LMNA | |
| SCHEMBL12391542 | 0.82 | ALDH1A1 (0.69) | ALDH1A1KDM4EHPGDSMN1; SMN2LMNA | |
| Salethamide SCHEMBL11573255 | 0.82 | ALDH1A1 (0.69) | ALDH1A1KDM4EHPGDSMN1; SMN2LMNA | |
| SCHEMBL11374040 | 0.82 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDSMN1; SMN2LMNA | |
| SCHEMBL2442381 | 0.80 | KDM4E (0.54) | ALDH1A1KDM4EHPGDSMN1; SMN2LMNA | |
| SCHEMBL28016258 | 0.80 | TSHR (0.77) | ALDH1A1HPGDSMN1; SMN2LMNATSHR | |
| SCHEMBL23488947 | 0.79 | ALDH1A1 (0.66) | ALDH1A1KDM4EHPGDSMN1; SMN2LMNA | |
| Hydrochloric Acid SCHEMBL2442318 | 0.79 | KDM4E (0.53) | ALDH1A1KDM4EHPGDSMN1; SMN2POLR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0821594-A1 | COMPOUNDS FOR CANCER IMAGING AND THERAPY | JOHN, Christy S. (US) | 1998-02-04 | — | — | EP | claimed |
| EP-0458886-B1 | AGENTS FOR DIAGNOSING AND TREATING MELANOMAS, AROMATIC HALOGENATED DERIVATIVES USABLE AS SUCH AGENTS AND THEIR PREPARATION | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 1993-10-13 | — | — | EP | claimed |
| WO-2025108921-A1 | SYNTHESIS OF RADIOPHARMACEUTICAL AGENTS | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-05-30 | — | — | WO | disclosed |
| US-10538485-B2 | Compounds for use as therapeutic agents affecting P53 expression and/or activity | ABIVAX (FR) | 2020-01-21 | — | — | US | disclosed |
| EP-2252605-B1 | LABELLED ANALOGUES OF HALOBENZAMIDES AS MULTIMODAL RADIOPHARMACEUTICALS AND THEIR PRECURSORS | INST NAT SANTE RECH MED (FR) | 2018-06-13 | — | — | EP | disclosed |
| US-20180127353-A1 | COMPOUNDS FOR USE AS THERAPEUTIC AGENTS AFFECTING P53 EXPRESSION AND/OR ACTIVITY | ABIVAX (FR) | 2018-05-10 | — | — | US | disclosed |
| US-9890112-B2 | Compounds for use as therapeutic agents affecting p53 expression and/or activity | ABIVAX (FR) | 2018-02-13 | — | — | US | disclosed |
| EP-2841402-B1 | LABELLED QUINOXALINE DERIVATIVES AS MULTIMODAL RADIOPHARMACEUTICALS AND THEIR PRECURSORS | INST NAT SANTÉ ET DE LA RECH MÉDICALE (FR) | 2016-11-30 | — | — | EP | disclosed |
| US-9125937-B2 | Labelled analogues of halobenzamides as multimodal radiopharmaceuticals and their precursors | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2015-09-08 | — | — | US | disclosed |
| US-20150079000-A1 | Labelled Quinoxaline Derivatives as Multimodal Radiopharmaceuticals and Their Precursors | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2015-03-19 | — | — | US | disclosed |
| EP-2841402-A1 | LABELLED QUINOXALINE DERIVATIVES AS MULTIMODAL RADIOPHARMACEUTICALS AND THEIR PRECURSORS | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2015-03-04 | — | — | EP | disclosed |
| WO-2013160808-A1 | LABELLED QUINOXALINE DERIVATIVES AS MULTIMODAL RADIOPHARMACEUTICALS AND THEIR PRECURSORS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2013-10-31 | — | — | WO | disclosed |
| EP-2657213-A1 | Labelled quinoxaline derivatives as multimodal radiopharmaceuticals and their precursors | Institut National de la Santé et de la Recherche Medicale (FR) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012131656-A2 | COMPOUNDS FOR USE AS THERAPEUTIC AGENTS AFFECTING P53 EXPRESSION AND/OR ACTIVITY | SOCIÉTÉ SPLICOS (FR) | 2012-10-04 | — | — | WO | disclosed |
| EP-2505198-A1 | Compounds for use as therapeutic agents affecting p53 expression and/or activity | Société Splicos (FR) | 2012-10-03 | — | — | EP | disclosed |
| EP-2046789-B1 | LABELLED ANALOGUES OF HALOBENZAMIDES AS RADIOPHARMACEUTICALS | INST NAT SANTE RECH MED (FR) | 2012-09-05 | — | — | EP | disclosed |
| EP-2363399-A1 | Labelled analogues of halobenzamides as radiopharmaceuticals | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2011-09-07 | — | — | EP | disclosed |
| US-20110044899-A1 | LABELLED ANALOGUES OF HALOBENZAMIDES AS MULTIMODAL RADIOPHARMACEUTICALS AND THEIR PRECURSORS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2011-02-24 | — | — | US | disclosed |
| US-20100061928-A1 | LABELLED ANALOGUES OF HALOBENZAMIDES AS RADIOPHARMACEUTICALS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2010-03-11 | — | — | US | disclosed |
| EP-2085390-A1 | Labelled analogues of halobenzamides as multimodal radiopharmaceuticals and their precursors | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2009-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150079000-A1 | Labelled Quinoxaline Derivatives as Multimodal Radiopharmaceuticals and Their Precursors | HRH3, SSTR3, MC3R | ALDH1A1 2429/4885KDM4E 4368/4885HPGD 3140/4885 |
| US-20100061928-A1 | LABELLED ANALOGUES OF HALOBENZAMIDES AS RADIOPHARMACEUTICALS | HRH3, H1-3, HRH4 | ALDH1A1 794/4885KDM4E 3466/4885HPGD 2171/4885 |
| US-20180127353-A1 | COMPOUNDS FOR USE AS THERAPEUTIC AGENTS AFFECTING P53 EXPRESSION AND/OR ACTIVITY | TP53, TP53BP1, BCOR | ALDH1A1 3337/4885KDM4E 4115/4885HPGD 2019/4885 |
| US-10538485-B2 | Compounds for use as therapeutic agents affecting P53 expression and/or activity | TP53, TP53BP1, BCOR | ALDH1A1 3337/4885KDM4E 4115/4885HPGD 2019/4885 |
| US-20110044899-A1 | LABELLED ANALOGUES OF HALOBENZAMIDES AS MULTIMODAL RADIOPHARMACEUTICALS AND THEIR PRECURSORS | CBR3, ADRB3, HRH4 | ALDH1A1 1763/4885KDM4E 4623/4885HPGD 3011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.